Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 4/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3994450 | 0.91 | GNAO1 (0.56) | GNAO1ITGB3ITGA2BNCF1GNAI3 | |
| SCHEMBL245769 | 0.87 | NCF1 (0.56) | GNAO1NCF1GNAI3GNAI1ACHE | |
| SCHEMBL4036508 | 0.83 | NCF1 (0.48) | GNAO1ITGB3ITGA2BNCF1GNAI3 | |
| SCHEMBL24319448 | 0.82 | GNAO1 (0.53) | GNAO1NCF1GNAI3GNAI1ACHE | |
| SCHEMBL9675410 | 0.82 | GNAO1 (0.57) | GNAO1ITGB3ITGA2BGNAI3GNAI1 | |
| SCHEMBL11164665 | 0.82 | NCF1 (0.56) | GNAO1NCF1GNAI3GNAI1ACHE | |
| SCHEMBL237382 | 0.82 | ITGB3 (0.47) | GNAO1ITGB3ITGA2BGNAI3GNAI1 | |
| SCHEMBL16079060 | 0.81 | GNAO1 (0.69) | GNAO1ITGB3ITGA2BGNAI3GNAI1 | |
| SCHEMBL13183482 | 0.80 | GNAO1 (0.58) | GNAO1ITGB3ITGA2BGNAI3GNAI1 | |
| SCHEMBL11157613 | 0.80 | NCF1 (0.54) | GNAO1NCF1GNAI3GNAI1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005763-B2 | Photochromic compounds | TRANSITIONS OPTICAL, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3002287-B1 | Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors | NAT DEFENSE MEDICAL CENTER (TW) | 2018-01-31 | — | — | EP | disclosed |
| US-20160332995-A1 | Photochromic Comounds | TRANSITIONS OPTICAL, INC. | 2016-11-17 | — | — | US | disclosed |
| US-9469728-B2 | Temperature and pH-sensitive block copolymer having excellent safty in vivo and hydrogel and drug delivery system using thereof | SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE (KR) | 2016-10-18 | — | — | US | disclosed |
| US-9405041-B2 | Photochromic compounds | TRANSITIONS OPTICAL, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160209561-A1 | Photochromic Articles That Include Photochromic-Dichroic Materials | TRANSITIONS OPTICAL, INC. | 2016-07-21 | — | — | US | disclosed |
| US-9334439-B2 | Photochromic articles that include photochromic-dichroic materials | TRANSITIONS OPTICAL, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150197492-A1 | NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2015-07-16 | — | — | US | disclosed |
| US-9051332-B1 | Photochromic indeno-fused ring pyran compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150141661-A1 | Photochromic Indeno-Fused Ring Pyran Compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-9029565-B1 | Fused ring indeno compounds for preparation of photochromic compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-8927717-B1 | Thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2015-01-06 | — | — | US | disclosed |
| US-20140272468-A1 | PHOTOCHROMIC ARTICLES THAT INCLUDE PHOTOCHROMIC-DICHROIC MATERIALS | TRANSITIONS OPTICAL, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140154514-A1 | PHOTOCHROMIC COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8582192-B2 | Polarizing photochromic articles | TRANSITIONS OPTICAL, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110279883-A1 | POLARIZING PHOTOCHROMIC ARTICLES | TRANSITIONS OPTICAL, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110140056-A1 | Indeno-fused ring compounds | TRANSITIONS OPTICAL, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-5175158-A | CONDENSED DIAZEPINONES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | DR. KARL THOMAE, GMBH (DE) | 1992-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332995-A1 | Photochromic Comounds | CCR4, CCR3, CCR8 | GNAO1 794/4885ITGB3 346/4885ITGA2B 2185/4885 |
| US-10005763-B2 | Photochromic compounds | CCR4, CCR8, CBR3 | GNAO1 509/4885ITGB3 415/4885ITGA2B 2177/4885 |
| US-20110140056-A1 | Indeno-fused ring compounds | CRY2, SQOR, INTS6 | GNAO1 3043/4885ITGB3 2010/4885ITGA2B 1364/4885 |
| US-20150141661-A1 | Photochromic Indeno-Fused Ring Pyran Compounds | INF2, INCENP, RB1 | GNAO1 1945/4885ITGB3 2529/4885ITGA2B 3501/4885 |
| US-20150197492-A1 | NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF | TOP1, TOP2A, TOP2B | GNAO1 2028/4885ITGB3 4628/4885ITGA2B 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.